Application of modified Charlson comorbidity index for predicting outcomes following adult living donor liver transplantation

Figure 1 Diagram showing frequency distribution of modified Charlson comorbidity index in our study.

Figure 2 Distribution of high (orange bars) and low modified Charlson comorbidity index patients (blue bars) across various etiology of liver disease in our study. HCC: Hepatocellular carcinoma; MASH: Metabolic dysfunction-associated steatohepatitis; mCCI: Modified Charlson comorbidity index.

Figure 3 Morbidity and 90-day mortality in different classes of modified Charlson comorbidity index. A: Morbidity; B: 90-day mortality. Blue bars: Relative frequency of patients with morbidity and mortality. Orange bars: Non-morbid patients.

Figure 4 Mortality in different groups of preoperative models for end-stage liver disease and modified Charlson comorbidity index category. mCCI: Modified Charlson comorbidity index; MELD: Model for end-stage liver disease.

Figure 5 Box and whisker plots for the combined score [modified Charlson comorbidity index + (preoperative model for end-stage liver disease/10)] in patients with morbidity and 90-day mortality. A: Morbidity; B: 90-day mortality. mCCI: Modified Charlson comorbidity index; MELD: Model for end-stage liver disease.